Ampio Pharmaceuticals Inc Stock News
$0.241
+0.0155 (+6.89%)
At Close: May 07, 2024
Why These 3 Penny Stocks Are Climbing in Late April
08:20pm, Friday, 22'nd Apr 2022 PennyStocks
Are these three penny stocks on your watchlist right now?
The post Why These 3 Penny Stocks Are Climbing in Late April appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStock
Why These 3 Penny Stocks Are Climbing in Late April
04:20pm, Friday, 22'nd Apr 2022
Are these three penny stocks on your watchlist right now? The post Why These 3 Penny Stocks Are Climbing in Late April appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStock
Ampio Pharma Shares Fall As FDA Rejects Proposed Change In Knee Osteoarthritis Trial
10:26am, Thursday, 21'st Apr 2022 Benzinga
Ampio Pharmaceuticals Inc (NYSE: AMPE) received written responses from the FDA pursuant to a Type C meeting request regarding the AP-013 Phase 3 trial results.
In March, Ampio announced data from t
Ampio Pharma Shares Fall As FDA Rejects Proposed Change In Knee Osteoarthritis Trial
06:29am, Thursday, 21'st Apr 2022
Ampio Pharmaceuticals Inc (NYSE: AMPE) received written responses from the FDA pursuant to a Type C meeting request regarding the AP-013 Phase 3 trial results. In March, Ampio announced data from t
New Strong Sell Stocks for April 7th
11:04am, Thursday, 07'th Apr 2022 Zacks Investment Research
AMPE, ANIK, and FAT have been added to the Zacks Rank #5 (Strong Sell) List on April 7, 2022.
New Strong Sell Stocks for April 7th
08:17am, Thursday, 07'th Apr 2022
AMPE, ANIK, and FAT have been added to the Zacks Rank #5 (Strong Sell) List on April 7, 2022.
New Strong Sell Stocks for April 1st
10:35am, Friday, 01'st Apr 2022 Zacks Investment Research
AKYA, AMPE, and BITF have been added to the Zacks Rank #5 (Strong Sell) List on April 1, 2022.
New Strong Sell Stocks for April 1st
08:17am, Friday, 01'st Apr 2022
AKYA, AMPE, and BITF have been added to the Zacks Rank #5 (Strong Sell) List on April 1, 2022.
Ampio Pharmaceuticals, Inc. (AMPE) CEO Michael Martino on Q4 2021 Results - Earnings Call Transcript
06:41pm, Tuesday, 29'th Mar 2022
Ampio Pharmaceuticals, Inc. (AMPE) CEO Michael Martino on Q4 2021 Results - Earnings Call Transcript
The Daily Biotech Pulse: Sanofi-IGM Ink Antibody Drug Collaboration; NeoGenomics Sinks On CEO Departure, Q1 Warning; Decision Day For Akebia
11:41am, Tuesday, 29'th Mar 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Pfizer Announces Positive Results From Second Late-Stage Study Of Ulcerative Colitis Drug
Pfizer, Inc.
Benzinga's Top Ratings Upgrades, Downgrades For March 24, 2022
02:04pm, Thursday, 24'th Mar 2022 Benzinga
Upgrades
For iRobot Corp (NASDAQ:IRBT), Northland Capital Markets upgraded the previous rating of Market Perform to Outperform. In the fourth quarter, iRobot showed an EPS of $1.05, compared to $0.84
Why Ampio Pharmaceuticals Stock Is Rising Today
01:35pm, Thursday, 24'th Mar 2022 Benzinga
Ampio Pharmaceuticals Inc (AMEX:AMPE) shares are trading significantly higher Thursday following bullish analyst coverage.
Alliance Global Partners analyst James Molloy initiated coverage on Ampio Ph
Why Ampio Pharmaceuticals Stock Is Rising Today
09:41am, Thursday, 24'th Mar 2022
Ampio Pharmaceuticals Inc (AMEX:AMPE) shares are trading significantly higher Thursday following bullish analyst coverage. Alliance Global Partners analyst James Molloy initiated coverage on Ampio Ph
The Daily Biotech Pulse: NuCana Shelves Biliary Tract Cancer Study, Tricida Data Readout Pushed Back Due to Ukrainian Crisis, Synlogic Names New CFO
12:46pm, Thursday, 03'rd Mar 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
NuCana Discontinues Biliary Tract Cancer Study Following Futility Analysis
NuCana plc (NASDAQ: NCNA) s
Ampio Highlights Promising Ampion Data In Knee Osteoarthritis
11:14am, Thursday, 03'rd Mar 2022 Benzinga
Ampio Pharmaceuticals Inc (NYSE: AMPE ) announced data from the modified Intent-to-Treat (mITT) population in the AP-013 Phase 3 trial of Ampion in severe osteoarthritis of the knee (OAK). The AP-013 study was designed to confirm the efficacy observed in the first pivotal trial, AP-003-A, and was powered to detect treatment differences between Ampion and saline control. In the mITT population (n = 618), which retained more than 85% power … Full story available on Benzinga.com
